Carregando empresa
Just reported
From Labcorp's results release of 28 de outubro de 2026; its quarterly report has since been filed.
Actual
US$ 3,81B
+6,9% y/y
+2,1% q/q
Guided
—
No guide given
Actual
US$ 3,22
+3,2% y/y
-12% q/q
Guided
—
No guide given
Actual
US$ 402,1M
+1,4% y/y
-11% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
As participações na receita são estimativas para year ended 2025-12-31, não números de um relatório oficial.
Routine and specialty diagnostic tests
Laboratory tests on patient samples, including tests used to diagnose and monitor diseases, as well as occupational, wellness and forensic deoxyribonucleic acid (DNA) testing.
ColoSense
A stool-based colorectal cancer screening test that people collect at home; it is approved by the U.S. Food and Drug Administration (FDA).
PlasmaDetect genome minimal residual disease (MRD)
A blood test being evaluated for monitoring whether early-stage lung cancer returns after treatment.
Labcorp OnDemand
A service through which consumers can order certain health and wellness tests directly, including tests for cancer screening, allergies and men's and women's health.
Central laboratory services
Laboratory testing for pharmaceutical and biotechnology companies conducting clinical studies of medicines.
Early development laboratory services
Laboratory services supporting early stages of drug research and development.
Demonstrações financeiras completas →
Labcorp tests patient samples at its laboratories, performing routine and specialty tests for diagnosing and monitoring health conditions. Its Biopharma Laboratory Services business performs laboratory work for pharmaceutical, biotechnology, medical device and diagnostic companies, including central laboratory testing and early development services. Patients can also order some tests directly through Labcorp OnDemand.
Construído a partir dos próprios documentos de Labcorp Holdings Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
The themes Labcorp is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Labcorp sells medical testing to doctors, hospitals, health plans and patients, plus drug-development laboratory testing to pharmaceutical and biotechnology companies.
Grade A
A faixa sob o preço mostra a nota em cada data, calculada só com os documentos já públicos naquele momento.
Mostrando 2 de 41 trimestres do histórico de notas de Labcorp Holdings Inc.. Os outros 39 vão até outubro de 2016.
